CD276 and neoplasm: Elevated expression of immune-checkpoint cell surface antigen CD276 on tumor cells has been reported to be associated with poor prognosis, suggesting the suppression of anti-tumor immune responses of host T lymphocytes towards the CD276-bearing tumor cells [62,63,64,65].